Nurix Therapeutics (NRIX) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 131.2% versus a gain of 41.2%. Over five years, PHVS leads with a +100.5% price change compared with -21.2% for NRIX. Nurix Therapeutics is the larger company by market cap ($2.36 billion vs $2.22 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | PHVS |
|---|---|---|
| Share price | $22.73 | $31.68 |
| Market cap | $2.36B | $2.22B |
| 1-day change | +0.58% | +1.80% |
| YTD return | +19.82% | +14.16% |
| 1-year return | +131.23% | +41.18% |
| 5-year return | -21.16% | +100.51% |
| EPS (TTM) | $-3.46 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.23 | $43.25 |
| 52-week low | $9.00 | $20.65 |
| Distance from 52-week high | -19.48% | -26.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +49.27% | +80.62% |
| Average volume | 1.27M | 740.93K |
| Shares outstanding | 103.78M | 70.20M |
| Employees | 317 | 148 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed PHVS by 90.1 percentage points over the past year.
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
NRIX vs PHVS FAQ
Which is bigger, Nurix Therapeutics or Pharvaris N.V.?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $2.36B compared with $2.22B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, NRIX or PHVS?
NRIX returned +131.23% over the past 12 months, compared with +41.18% for PHVS (price return, excluding dividends). Past performance does not predict future results.
Are Nurix Therapeutics and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.